Drug · CHEMBL1456

MYCOPHENOLATE MOFETIL

7 sourcespipelines-2026-09-18-0.3.1

Cite this record

ConductScience Library. MYCOPHENOLATE MOFETIL. Drugs and targets, record CHEMBL1456. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL1456

On this page

Drug

Names and IDs as ChEMBL gives them, through Open Targets.

Name: MYCOPHENOLATE MOFETIL; ChEMBL
ChEMBL ID: CHEMBL1456; ChEMBL
Type: Small molecule; ChEMBL
Brand names: Arzip, Cellcept, Myclausen, Mycophenolate mofetil teva, Myfenax, Myhibbin; ChEMBL
Other names: Myclausen, Mycophenolic acid 2-(4-morpholinyl)ethyl ester, Mycophenylate mofetil, Myhibbin, NSC-724229, NSC-758905, RS-61443; ChEMBL
Other form: MYCOPHENOLATE MOFETIL HYDROCHLORIDE, CHEMBL1200955; Drugs and targets
DrugBank: DB00688; DrugBank
InChIKey: RTGDFNSFWBGLEC-SYZQJQIISA-N; ChEMBL
Open Targets' highest stage: Approval, as Open Targets' drug record gives it; Open Targets

Targets2

The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.

Target	Protein	Mechanism	Action	Gene in Genes
IMPDH1	Inosine-5'-monophosphate dehydrogenase (IMPDH)	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor	INHIBITOR	https://conductscience.org/library/genes/3614
IMPDH2	Inosine-5'-monophosphate dehydrogenase (IMPDH)	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor	INHIBITOR	https://conductscience.org/library/genes/3615

Source ChEMBL

Diseases168

The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Disease	Open Targets' stage	Stage reported by	Reports	Of them trials	Its drugs
hematopoietic and lymphoid cell neoplasm	Phase 3	ClinicalTrials.gov	73	73	https://conductscience.org/library/drugs?q=MONDO_0044881
lupus nephritis	Phase 3	ClinicalTrials.gov	30	30	https://conductscience.org/library/drugs?q=MONDO_0005556
acute myeloid leukemia	Phase 3	ClinicalTrials.gov	27	27	https://conductscience.org/library/drugs?q=MONDO_0018874
myelodysplastic syndrome	Phase 3	ClinicalTrials.gov	25	25	https://conductscience.org/library/drugs?q=MONDO_0018881
graft versus host disease	Phase 3	ClinicalTrials.gov	14	14	https://conductscience.org/library/drugs?q=MONDO_0013730
acute lymphoblastic leukemia	Phase 3	ClinicalTrials.gov	13	13	https://conductscience.org/library/drugs?q=MONDO_0004967
aplastic anemia	Phase 2/3	ClinicalTrials.gov	13	13	https://conductscience.org/library/drugs?q=MONDO_0015909
plasma cell myeloma	Phase 2	ClinicalTrials.gov	13	13	https://conductscience.org/library/drugs?q=MONDO_0009693
lymphoma	Phase 2	ClinicalTrials.gov	12	12	https://conductscience.org/library/drugs?q=MONDO_0005062
type 1 diabetes mellitus	Phase 2	ClinicalTrials.gov	12	12	https://conductscience.org/library/drugs?q=MONDO_0005147

1 to 10 of 168Source Open Targets

See all 168 diseases

Trials698

Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 2 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Named as	Linked by	Source
NCT00300274	Efficacy and Safety of Everolimus in Recipients of Heart Transplants to Prevent Acute and Chronic Rejection	Phase 3	721	2012-08-16	mycophenolate mofetil	Its name	ClinicalTrials.gov
NCT00064701	Comparative Study of Modified Release (MR) Tacrolimus/Mycophenolate Mofetil (MMF) in de Novo Kidney Transplant Recipients	Phase 3	668	2013-09-26	mycophenolate mofetil	Its name	ClinicalTrials.gov
NCT01062555	Calcineurin Inhibitor Sparing After Kidney Transplantation	Phase 1/2	527	2020-12-14	mycophenolate mofetil	Its name	ClinicalTrials.gov
NCT00113269	Safety/Efficacy of Induction Agents With Tacrolimus, MMF, and Rapid Steroid Withdrawal in Renal Transplant Recipients	Phase 4	501	2011-07-08	mycophenolate mofetil	Its name	ClinicalTrials.gov
NCT00048165	A Study to Evaluate the Efficacy and Safety of Zenapax in Combination With CellCept, Cyclosporine, and Corticosteroids in Patients Undergoing Cardiac Transplantation	Phase 4	434	2016-06-13	mycophenolate mofetil	Its name	ClinicalTrials.gov
NCT03959241	TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)	Phase 3	431	2024-01-12	mycophenolate mofetil	Its name	ClinicalTrials.gov
NCT00430677	Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis	Phase 2/3	423	2012-05-11	mycophenolate mofetil	Its name	ClinicalTrials.gov
NCT00400400	Enteric-coated Mycophenolate Sodium (EC-MPS) and Mycophenolate Mofetil (MMF) in Renal Transplant Patients With Gastrointestinal (GI) Intolerance	Phase 4	400	2011-08-15	mycophenolate mofetil	Its name	ClinicalTrials.gov
NCT00377637	A Study of Mycophenolate Mofetil (CellCept) in Management of Patients With Lupus Nephritis.	Phase 3	370	2011-12-06	mycophenolate mofetil	Its name	ClinicalTrials.gov
NCT00303719	Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy	Phase 2	342	2020-05-12	mycophenolate mofetil	Its name	ClinicalTrials.gov

1 to 10 of 698

See all 698 trials

Comparisons in its trials296

Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Daclizumab vs Placebo: Number of Participants Who Developed Acute Rejection Episode Within 6 Months Post-Transplant	77 of 216	104 of 218	434	NCT00048165	Trial comparisons
Daclizumab vs Placebo: Number of Participants Who Developed Acute Rejection Episode Within the 12 Months PT	97 of 216	116 of 218	434	NCT00048165	Trial comparisons
PTCY/Tacrolimus/MMF vs Tacrolimus/Methotrexate: deaths from any cause	58 of 214	70 of 217	431	NCT03959241	Trial comparisons
Daclizumab vs Placebo: serious adverse events	108 of 216	102 of 207	423	NCT00048165	Trial comparisons
PTCY/Tacrolimus/MMF vs Tacrolimus/Methotrexate: serious adverse events	7 of 208	14 of 212	420	NCT03959241	Trial comparisons
Enteric-coated Mycophenolate Sodium vs Mycophenolate Mofetil: serious adverse events	7 of 199	11 of 197	396	NCT00400400	Trial comparisons
High Risk Patients vs Standard Risk Patients: Acute Graft-Versus-Host Disease	2 of 13	79 of 292	305	NCT00303719	Trial comparisons
High Risk Patients vs Standard Risk Patients: Serious Adverse Events	0 of 13	47 of 292	305	NCT00303719	Trial comparisons
High Risk Patients vs Standard Risk Patients: Overall Survival	8 of 13	181 of 292	305	NCT00303719	Trial comparisons
High Risk Patients vs Standard Risk Patients: Transplant Related Mortality	2 of 13	40 of 292	305	NCT00303719	Trial comparisons

1 to 10 of 296

See all 296 comparisons in its trials

Papers from its trials426

The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
40960806	RESULT	1	PubMed
39490986	RESULT	1	PubMed
38281591	RESULT	1	PubMed
37294447	RESULT	1	PubMed
37230499	RESULT	1	PubMed
36749914	RESULT	1	PubMed
36701644	RESULT	1	PubMed
36346684	RESULT	1	PubMed
35959915	RESULT	1	PubMed
35907408	RESULT	1	PubMed

1 to 10 of 426

See all 426 papers from its trials

Tests in its trials1

The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.

Test	Trials naming it as an outcome	As a primary outcome
Clock Drawing Task	1	0

Source ConductCognition

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
ClinicalTrials.gov: 2026-11-05; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
Papers the trials list, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
Tests named in the trials, as ScienceGraph matched them: 2026-11-12; ConductCognition

Sources 7

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ConductCognition's list of its testsOur own data
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this drug from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/drugs/v1/CHEMBL1456

GET https://conductscience.org/api/drugs/v1/CHEMBL1456/diseases?page=2

API reference For AI assistants